Medication info
Promet Tablets 50/850 mg

Promet Tablets 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
Deep pink oval film-coated tablets
Packaging
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204598 · Approved 2022.12.21 · Insurance code 654006010

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood glucose control in patients with type 2 diabetes by complementing dietary and exercise therapy. Specifically, it helps manage blood glucose more effectively through the combined administration of sitagliptin and metformin. This can stabilize blood glucose levels and be useful in improving diabetic conditions.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin and is used for the treatment of diabetes. First, when taking this medication, serious allergic reactions may occur, so if symptoms such as skin rash or difficulty breathing arise, you should immediately stop taking the medication and consult a doctor. Second, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so you should inform the healthcare professional immediately if you experience abdominal pain, vomiting, or severe abdominal discomfort. Third, due to the metformin component, there is a risk of lactic acidosis, a rare but life-threatening metabolic disorder, so if symptoms such as sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occur, visit the hospital immediately. Fourth, patients with poor kidney function, severe infections or dehydration, or heart failure should not take this medication, especially as they should have regular kidney function tests. Fifth, this medication is not recommended for use in pregnant or nursing women, or in children under 18 years of age. Sixth, it is important to avoid alcohol consumption while taking this medication, as excessive drinking can increase the risk of lactic acidosis. Seventh, if this medication is used with other hypoglycemic agents such as insulin or sulfonylureas, the risk of hypoglycemia increases, so blood glucose levels should be monitored closely. Eighth, before and after surgery, this medication should be temporarily discontinued, and it can be resumed once food intake has normalized and kidney function is confirmed to be normal. Ninth, during the course of taking this medication, regular blood tests and kidney function tests are necessary to check for any abnormalities. Finally, this medication may cause side effects such as diarrhea, nausea, headache, and upper respiratory infections in some patients, so if symptoms are severe, consult your healthcare professional.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 19 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesiculo-bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that can block air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness over time.

Appearance and packaging

Appearance

Deep pink oval film-coated tablets

Package unit

56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.